Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232191 · ClinicalTrials.gov registry record · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
A Phase 2 study of Asplenia, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT02232191 is a Phase 2 study of Asplenia that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02232191, a Phase 2 study of Asplenia, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
Conditions Studied
Interventions
- BIOLOGICAL Pneumovax-23
Study Locations (1)
California
- University of California, Davis Medical Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-12 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02232191
The ClinicalTrials.gov registry entry for NCT02232191 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asplenia appearing as the primary indexed condition, and to 1 intervention - of which Pneumovax-23 is the first listed.
NCT02232191 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02232191 about?
NCT02232191 is a clinical study titled "Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients". Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen cur...
What is the current status of trial NCT02232191?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-12. Estimated completion is 2026-07.
What conditions does trial NCT02232191 study?
This clinical trial studies the following conditions: Asplenia.
What interventions are being tested in trial NCT02232191?
The interventions under investigation include: Pneumovax-23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02232191?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02232191 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.